Comparing the major recovery peptide protocols

Comparing recovery peptide protocols sounds like a simple ranking exercise — pick the best one and run it. It isn't, because the major protocols address different layers of the recovery problem and aren't interchangeable. The most-reported protocol for a chronic Achilles isn't the same as the most-defensible protocol for whole-body post-overtraining recovery, and neither matches what gets used after surgery.

This is a long comparison of the major recovery peptide protocols — what each does, what evidence supports it, where it fits, and where it doesn't. Then a decision framework at the end matching common scenarios to the most-defensible starting point.

The protocols in scope

We'll cover the five protocols that account for the bulk of serious recovery use:

These aren't the only recovery peptides ever used, but they're the ones that show up consistently in real protocols. We're skipping fringe and barely-studied compounds, plus things like collagen peptides that are food, not signaling molecules.

What each protocol actually does

BPC-157 is a 15-amino-acid synthetic peptide. The mechanism most cited is local angiogenesis and growth-factor recruitment at sites where it's administered, plus systemic effects when run for weeks. Best pre-clinical evidence: tendon, ligament, gut, neural tissue. Daily SubQ, typical 250-500 mcg. Cycles run 4-8 weeks for acute and up to 12 weeks for chronic.

TB-500 is a 17-amino-acid fragment of thymosin beta-4. It binds and regulates G-actin, the cytoskeletal protein, and signals systemic cell migration toward injury. Long tissue half-life — twice-weekly during a loading phase, then every 1-2 weeks for maintenance. Effect is whole-body and accumulates over weeks.

The BPC + TB stack runs both simultaneously. BPC-157 acts locally; TB-500 acts systemically. The rationale is non-overlapping mechanisms — angiogenesis plus actin-mediated cell migration — and the stack is the most-reported protocol for stubborn tendon and ligament injuries.

GHK-Cu is a copper-binding tripeptide. Skin remodeling, wound healing, hair-follicle research applications. Topical formulations dominate cosmetic use; SubQ is more common when broader effects are wanted. Different category from the four above — it's not driving skeletal-muscle or tendon repair primarily.

IGF-1 LR3 is a long-acting analog of IGF-1. It's an anabolic signal more than a recovery signal — drives muscle protein synthesis and tissue growth. Used in defined short blocks (4-6 weeks) at low daily doses. Different risk profile than the others; closer to anabolic territory.

Mechanism comparison

The "local + systemic" distinction matters. BPC-157 injected near an injury concentrates effect there; TB-500 distributes regardless of injection site. That's why the stack rationale works — they don't overlap.

Evidence comparison

Honest read of the evidence base behind each:

None of these are FDA-approved for the uses described. All are research chemicals or off-label depending on jurisdiction. The evidence ranking isn't "which works best" — it's "which has the most science behind the protocol you're considering."

Cost comparison

12-week cycle approximations, US:

Cost ranking only matters if you've matched the protocol to the indication. The stack is cheaper than three rounds of PRP for the same injury, but it's pointless cost if the injury is structural and needs surgery.

Side-effect profile comparison

IGF-1 LR3 sits in a different risk class than the others. It's a direct anabolic signal with hypoglycemia risk and the same theoretical tissue-growth concerns as HGH. The first three are gentler; GHK-Cu is the gentlest.

Where each protocol fits

BPC-157 alone fits:

• Acute, well-localized soft-tissue injury
• Recent strain, sprain, or pull
• GI inflammation focus
• Limited budget for a single peptide
• Want broader pre-clinical evidence

TB-500 alone fits:

• Whole-body post-overtraining recovery
• Multiple recurring small injuries
• Hard-to-localize systemic issues
• Less-frequent injection cadence preferred

BPC + TB stack fits:

• Stubborn chronic tendinopathy that hasn't moved on either alone
• Multi-site injury picture
• Post-surgical remodeling window (with surgeon awareness)
• Maximal recovery emphasis with budget for both

GHK-Cu fits:

• Skin and hair concerns (cosmetic primary)
• Wound healing adjunct
• Anti-aging stack add-on rather than core recovery
• Lowest-risk peptide entry point

IGF-1 LR3 fits:

• Defined hypertrophy block, not recovery primarily
• Users with experience and lab monitoring
• Specific tissue-growth goal where the risk-reward makes sense
• Not a starting protocol

When stacking adds, when it just adds cost

Stacking doesn't multiply benefit linearly. BPC + TB is the canonical stack because the mechanisms genuinely don't overlap and the most-reported outcomes for stubborn injuries support it. Adding GHK-Cu to that for joint or tendon work is more speculative — the GHK-Cu evidence is skin-dominant. Adding IGF-1 LR3 to a recovery stack changes the category of the protocol; you've moved from recovery to anabolic.

A reasonable approach: start with one peptide, establish baseline response, add a second only if there's a mechanistic case the first doesn't cover. "Stack everything" is rarely the most-defensible protocol; it's the most-expensive one.

Decision framework

1. First-ever recovery peptide cycle, focal recent injury. BPC-157 alone, 4-6 weeks daily SubQ near the site. Cheapest, broadest pre-clinical evidence, simplest to evaluate.

2. Chronic tendinopathy that has failed PT and one BPC-157 cycle. Add TB-500 — run the stack for 8-12 weeks. Most-reported protocol for this pattern.

3. Whole-body recovery from accumulated training damage, no specific focal injury. TB-500 alone with loading protocol. Better fit than BPC for a diffuse picture.

4. Post-surgical soft-tissue recovery, surgeon aware. BPC + TB stack during the remodeling window. Coordinate with the surgical team.

5. GI inflammation focus (mild, not active IBD flare). BPC-157 alone, oral or SubQ. The most-clinically-promising indication for BPC-157.

6. Skin and hair concerns dominant, recovery secondary. GHK-Cu, topical first, SubQ if broader effect wanted. Don't expect tendon results.

7. Defined hypertrophy block, not recovery. IGF-1 LR3 with eyes open and ideally lab work. Not a starting peptide.

8. Anti-aging stack add-on, low-risk-tolerance user. GHK-Cu and a low-dose Sermorelin cycle elsewhere on the site. Skip IGF-1 LR3 in this profile.

When recovery peptides aren't the answer

Worth saying clearly. None of these protocols are the right answer when:

• The injury is structural and surgical
• The diagnosis is unclear (treat what you don't know with diagnosis, not signaling)
• Active or recent malignancy is in the picture
• The underlying problem is overtraining, undersleeping, or undereating — fundamentals first
• You're trying to skip rehab; recovery peptides are an adjunct, not a replacement
• Active cancer history or strong family history without oncology-aware conversation

A signaling peptide multiplies a healing process that's already moving. It's not an ignition for a process that hasn't started.

Related reading

• BPC-157 vs TB-500 — focused comparison
• Recovery stack — BPC-157 + TB-500
• BPC-157 complete guide
• TB-500 complete guide
• Stacking and cycling principles